ArticleJournal of clinical microbiology2015
Evaluation of portability and cost of a fluorescent PCR ribotyping protocol for Clostridium difficile epidemiology.
Article in Journal of clinical microbiology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed.
- Trial
- Antimicrobial susceptibility and ribotypes of Clostridium difficile isolates from a Phase 2 clinical trial of ridinilazole (SMT19969) and vancomycin.The Journal of antimicrobial chemotherapy · 2018Trial
- Protocol to study recurrence of Clostridioides difficile infection in murine model with built-in colonization and contamination controls.STAR protocols · 2026Article
- Article
- Emergence and Spread of Clostridioides difficile Isolates With Reduced Fidaxomicin Susceptibility in an Acute Care Hospital.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2025Article
- Molecular Epidemiology ofOpen forum infectious diseases · 2024Article
- Antibacterial activity of ibezapolstat against antimicrobial-resistant clinical strains ofAntimicrobial agents and chemotherapy · 2024Article
- Incubation period ofAntimicrobial stewardship & healthcare epidemiology : ASHE · 2024Article
- Discrimination between hypervirulent and non-hypervirulent ribotypes of Clostridioides difficile by MALDI-TOF mass spectrometry and machine learning.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2023Article
- A US-based national surveillance study for the susceptibility and epidemiology ofAntimicrobial agents and chemotherapy · 2023Article
- Higher In Vivo Fecal Concentrations of Clostridioides difficile Toxins A and B in Patients With North American Pulsed-Field Gel Electrophoresis Type 1/Ribotype 027 Strain Infection.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2022Article
- Multi-country surveillance of Clostridioides difficile demonstrates high prevalence of spores in non-healthcare environmental settings.Anaerobe · 2022Article
- Article
- Changes in the Association Between Diagnostic Testing Method, Polymerase Chain Reaction Ribotype, and Clinical Outcomes From Clostridioides difficile Infection: One Institution's Experience.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2021Article
- A multisite genomic epidemiology study ofMicrobial genomics · 2021Article
- Anti-toxin antibody is not associated with recurrent Clostridium difficile infection.Anaerobe · 2021Article
- Defining the black box: a narrative review of factors associated with adverse outcomes from severeTherapeutic advances in gastroenterology · 2021Review
- Clostridioides difficile carriage in animals and the associated changes in the host fecal microbiota.Anaerobe · 2020Article
- Detection and elimination of a novel non-toxigenicGut microbes · 2020Article
- In vitro activity of eravacycline against common ribotypes of Clostridioides difficile.The Journal of antimicrobial chemotherapy · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
Clostridium difficile is the most commonly identified pathogen among health care-associated infections in the United States. There is a need for accurate and low-cost typing tools that produce comparable data across studies (i.e., portable data) to help characterize isolates during epidemiologic investigations of C. difficile outbreaks and sporadic cases of disease. The most popular C. difficile-typing technique is PCR ribotyping, and we previously developed methods using fluorescent PCR primers and amplicon sizing on a Sanger-style sequencer to generate fluorescent PCR ribotyping data. This technique has been used to characterize tens of thousands of C. difficile isolates from cases of disease. Here, we present validation of a protocol for the cost-effective generation of fluorescent PCR ribotyping data. A key component of this protocol is the ability to accurately identify PCR ribotypes against an online database (http://walklab.rcg.montana.edu) at no cost. We present results from a blinded multicenter study to address data portability across four different laboratories and three different sequencing centers. Our standardized protocol and centralized database for typing of C. difficile pathogens will increase comparability between studies so that important epidemiologic linkages between cases of disease and patterns of emergence can be rapidly identified.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.